Idera Pharmaceuticals, Inc. (IDRA) EPS Estimated At $-0.08

February 20, 2018 - By Richard Conner

 Idera Pharmaceuticals, Inc. (IDRA) EPS Estimated At $ 0.08
Investors sentiment decreased to 1.36 in 2017 Q3. Its down 0.10, from 1.46 in 2017Q2. It dived, as 5 investors sold Idera Pharmaceuticals, Inc. shares while 20 reduced holdings. 11 funds opened positions while 23 raised stakes. 46.97 million shares or 1.60% more from 46.23 million shares in 2017Q2 were reported.
Connor Clark & Lunn Investment Mngmt Limited invested in 122,025 shares. The Pennsylvania-based Vanguard Gp has invested 0% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Panagora Asset Mgmt has 7,856 shares. Natixis reported 0.07% stake. Tci Wealth Advsr owns 0% invested in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) for 2,400 shares. Deutsche Bancorp Ag invested in 0% or 96,675 shares. Broadfin Cap Limited Com holds 0.8% or 2.43M shares in its portfolio. Voya Mgmt Ltd Llc stated it has 0% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Mycio Wealth Prtn Llc holds 246,527 shares. State Bank Of America Corp De holds 0% or 11,247 shares in its portfolio. Parametric Assocs Lc holds 0% or 11,932 shares. Northern Tru Corporation holds 0% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) or 1.25M shares. Geode Capital Mgmt Ltd Company owns 998,697 shares. Ameritas Inv Prtn Incorporated reported 0% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Tower Limited Liability Corporation (Trc) has 12,203 shares for 0% of their portfolio.

Since October 26, 2017, it had 1 insider buy, and 2 sales for $7.00 million activity. On Thursday, October 26 BAKER BROS. ADVISORS LP bought $12.00M worth of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) or 8.00 million shares.

Analysts expect Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) to report $-0.08 EPS on March, 21.They anticipate $0.09 EPS change or 900.00 % from last quarter’s $0.01 EPS. After having $-0.10 EPS previously, Idera Pharmaceuticals, Inc.’s analysts see -20.00 % EPS growth. The stock increased 1.05% or $0.02 during the last trading session, reaching $1.93. About 1.32M shares traded. Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has risen 21.13% since February 20, 2017 and is uptrending. It has outperformed by 4.43% the S&P500.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ratings Coverage

Among 4 analysts covering Idera Pharma (NASDAQ:IDRA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Idera Pharma had 7 analyst reports since January 6, 2016 according to SRatingsIntel. The stock of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) earned “Buy” rating by H.C. Wainwright on Thursday, November 16. On Wednesday, January 6 the stock rating was initiated by Wedbush with “Outperform”. Piper Jaffray maintained it with “Buy” rating and $4.0 target in Monday, September 11 report. As per Thursday, November 9, the company rating was maintained by Piper Jaffray. The company was maintained on Wednesday, February 1 by Wedbush.

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company has market cap of $377.58 million. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense technology. It currently has negative earnings. The company's drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis.

More notable recent Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) news were published by: which released: “Why II-VI, Sanmina, and Idera Pharmaceuticals Slumped Today” on January 22, 2018, also with their article: “BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming …” published on February 19, 2018, published: “RM LAW Announces Investigation of Idera Pharmaceuticals, Inc.” on January 30, 2018. More interesting news about Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) were released by: and their article: “Bragar Eagel & Squire, PC is Investigating the Board of Directors of Idera …” published on January 22, 2018 as well as‘s news article titled: “BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine …” with publication date: January 22, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.